ReposiTrak, Inc. (TRAK), the Utah-based software-as-a-service provider behind the ReposiTrak Traceability Network and food-supply-chain compliance platform, has fallen sharply from its 52-week high and now trades near its recent lows. With the stock recently changing hands around $7.12, the question for investors is whether shares can climb back toward the $16 level that remains the lone price target on Wall Street. The answer is not a simple yes or no: the $16 objective reflects a single analyst's view, and the required move is very large.
Unlike widely covered mega-caps, TRAK has very limited sell-side coverage. Aggregators such as TipRanks and MarketBeat currently show roughly one active analyst rating on the stock. That single view comes from Maxim Group analyst Tom Forte, who reiterated a Buy rating and a $16.00 price target in May 2026 and again in September 2026. Because only one credible, current, attributable target exists, there is no meaningful multi-analyst consensus to average; accordingly, the $16 figure here is presented as a single-analyst objective drawn from public discussion, not an analyst consensus.
For context, historical coverage shows a wider range of past views. Forte previously maintained an $11 target while at D.A. Davidson, and a dated data source lists an older $24 average. These are not current and are noted only to illustrate how thin and shifting TRAK's coverage has been. The relevant point is that the lone current target — $16 — represents a return to just above the stock's prior 52-week high, making it an ambitious but not arbitrary reference point.
ReposiTrak recently closed near $7.12, down sharply from its 52-week high around $15.44 and not far above its 52-week low near $6.61. Reaching $16 would require roughly a 125% advance — a very large move by any measure, and one that would effectively require the stock to recover all of its recent decline and then set new highs.
Fundamentally, ReposiTrak is a small, profitable SaaS (software-as-a-service) business. Fiscal 2026 revenue grew 3% to about $23.3 million, with recurring revenue up 4%, while net income reached roughly $7.4 million and EPS (earnings per share) about $0.39. The balance sheet is notably clean, with around $27 million in cash and minimal debt, and the company pays a modest dividend. The path to $16 would most likely depend on a reacceleration in traceability revenue as the FDA's compliance deadlines approach, rather than on any single quarter.
The chart shows a stock that broke down from levels near $15 to the low single digits. The $16 target sits just above the 52-week high near $15.44, making that area a key overhead resistance zone and prior high. On the downside, the 52-week low near $6.61 is an important support level; a sustained close below it would undermine the bullish case. Between these extremes, round-number levels such as $10 and $12 are likely to act as psychological resistance zones on any recovery.
A $16 price target of this kind generally reflects a roughly 12-month research horizon, though with a single analyst the timeframe is inherently less precise. Key items to watch include the company's next earnings report, management's commentary on traceability demand and the FDA timeline, the ramp of touchless retailing, any analyst revisions, and progress on the company's stated goal of redeeming remaining preferred shares. Regulatory milestones around the 2028 FDA deadline will be the most important long-term catalyst.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a small-cap name like TRAK with limited analyst coverage, these signals can offer an additional, data-driven way to track shifting momentum and identify turning points as they emerge. Traders can use the tool to discover opportunities, monitor existing positions, and spot changing trends more efficiently.
Can ReposiTrak (TRAK) stock reach $16? The target is real but rests on a single analyst's view rather than a broad consensus, and it demands a very large advance of roughly 125% from the current price near $7.12. The supporting case is anchored in regulatory tailwinds from food traceability requirements, a clean balance sheet, and recurring revenue, while the principal obstacles are a delayed FDA enforcement timeline, decelerating revenue growth, and thin coverage. For now, $16 represents a plausible return to the prior 52-week high rather than a near-term expectation, and investors should watch earnings, regulatory milestones, and any new analyst coverage for signals on whether that recovery thesis is gaining traction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TRAK has been loosely correlated with VERX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if TRAK jumps, then VERX could also see price increases.
| Ticker / NAME | Correlation To TRAK | 1D Price Change % | ||
|---|---|---|---|---|
| TRAK | 100% | -0.41% | ||
| VERX - TRAK | 49% Loosely correlated | +1.27% | ||
| OTEX - TRAK | 48% Loosely correlated | +0.20% | ||
| LSPD - TRAK | 47% Loosely correlated | +1.19% | ||
| SPSC - TRAK | 47% Loosely correlated | -1.16% | ||
| BL - TRAK | 46% Loosely correlated | +3.69% | ||
More | ||||
| Ticker / NAME | Correlation To TRAK | 1D Price Change % |
|---|---|---|
| TRAK | 100% | -0.41% |
| Packaged Software industry (222 stocks) | 27% Poorly correlated | -1.06% |
| Technology Services industry (396 stocks) | 22% Poorly correlated | -0.36% |